Oncology
Cancer clinical trials
Studies of cancers and tumors of every type and site, from prevention to treatment. We’re tracking 20,648 recruiting studies in this area right now.
By phase
- Not applicable9,813
- Phase 24,456
- Phase 12,744
- Phase 1/Phase 21,689
- Phase 31,402
- Phase 2/Phase 3281
- Phase 4263
Top conditions
- Breast Cancer1,229
- Cancer660
- Prostate Cancer656
- Colorectal Cancer493
- Lung Cancer426
- Ovarian Cancer341
- Multiple Myeloma330
- Gastric Cancer298
- Acute Myeloid Leukemia293
- Pancreatic Cancer292
- Hepatocellular Carcinoma284
- Solid Tumor258
- Advanced Solid Tumor257
- Cervical Cancer232
- Head and Neck Cancer227
- Endometrial Cancer206
- Advanced Solid Tumors195
- Esophageal Cancer191
Leading sponsors
- M.D. Anderson Cancer Center452
- Fudan University315
- Sun Yat-sen University291
- Memorial Sloan Kettering Cancer Center288
- National Cancer Institute (NCI)287
- Mayo Clinic240
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences151
- City of Hope Medical Center144
- AstraZeneca133
- University Health Network, Toronto125
Where studies are running
- California1,426
- Texas641
- Arizona510
- Florida450
- Alabama420
- New York410
- Massachusetts339
- Maryland330
- New Jersey269
- Pennsylvania240
Recruiting studies20,648 total
- NCT04415853RecruitingPhase 3
Larotinib for advanced esophageal cancer with high EGFR
This phase 3 trial tests larotinib, a targeted cancer medicine, for people with advanced or recurrent esophageal cancer that has high EGFR. It aims to see if it works better than standard treatment approaches after the cancer has progressed twice.
Beijing, Beijing MunicipalityAges 18–80 - NCT04414475RecruitingPhase 2
Selinexor plus low-dose steroid for hard-to-treat myeloma
This Phase 2 trial tests selinexor (a targeted anti-cancer medicine) plus low-dose dexamethasone to treat multiple myeloma that has not responded to many prior treatments. It compares selinexor combinations depending on what medicines you’ve already had, aiming to reduce myeloma activity and improve outcomes.
Pátrai, AchaiaAges 18 years+ - NCT04416165Recruiting
FDG versus FAPI PET scans for different cancers
This study compares two types of PET/CT scans—one that uses FDG and one that uses FAPI—to help doctors see and evaluate cancer in different situations. It may help improve how well scans detect tumors and guide care, though it requires getting both scans scheduled.
Xiamen, FujianAges 18–90 - NCT04417803Recruiting
Testing blood and tumor markers to guide lymphoma treatment
This study looks at “biomarkers” (measurable signs in your tumor and possibly blood) to understand your lymphoma’s genetic make-up. The goal is to see which markers may help doctors decide on treatment and timing.
DijonAges 18 years+ - NCT04421560RecruitingPhase 1/Phase 2
Testing pembrolizumab, ibrutinib, and rituximab for PCNSL
This Phase 1/2 study tests how well a combination of pembrolizumab, ibrutinib, and rituximab treats primary CNS lymphoma that came back or didn’t respond after prior brain treatment. It may help shrink the lymphoma and control it in the brain and fluid around the brain.
Boston, MassachusettsAges 18 years+ - NCT04420702Recruiting
MRI scan study to improve prostate detection
This trial studies special MRI images to learn how well they can find prostate cancer before treatment. It may help doctors choose better next steps during biopsy or during active surveillance.
St Louis, MissouriAges 18 years+ - NCT04421820RecruitingPhase 1/Phase 2
BOLD-100 with chemo for advanced gut cancer
This Phase 1/2 study tests whether BOLD-100, given with the standard chemo combination FOLFOX, can help people with advanced gastrointestinal cancers. It’s especially focused on specific tumor features (including BRAF status) and checks safety, dosing, and early signs of effectiveness.
Santa Monica, CaliforniaAges 18 years+ - NCT04422366RecruitingPhase 3
9-valent HPV vaccine study for healthy Chinese women
This trial tests a 9-type HPV vaccine to see how well it works, how it helps the body build protection, and whether it’s safe. It’s for healthy Chinese women who have not had HPV vaccination before and meet specific health and timing requirements.
Liuzhou, GuangxiAges 20–45 - NCT04425265Recruiting
Low-temperature plasma treatment vs high-frequency cautery for recurring cancer
This trial compares two ways of surgically treating localized, recurrent nasopharyngeal cancer: a low-temperature plasma radiofrequency method versus a standard high-frequency cautery method. You might be eligible if your recurrence is limited and can be surgically removed, and you are within the allowed health and age ranges.
Guangzhou, GuangdongAges 18–70 - NCT04424719Recruiting
Follow-up study for high-risk eye melanoma after treatment
This study follows people with high-risk uveal (eye) melanoma after their initial treatment to better understand relapse risk. It may help your care team track you more closely using scheduled visits and blood tests.
ParisAges 18 years+ - NCT04423484Recruiting
Treatment plan study for newly diagnosed one kidney tumor
This trial looks at what treatment recommendations work best for children with a nephroblastoma (Wilms tumor) that is in only one kidney and has not been treated yet. It may help doctors choose the best next steps for care while the child’s overall health supports treatment.
OuagadougouAges 6 months–18 years - NCT04425421Recruiting
Treatment plan for children with Burkitt lymphoma
This trial uses a recommended treatment approach for children who have Burkitt lymphoma, a specific type of blood cancer. It may help by guiding care when the full standard treatment schedule can’t be followed for every child.
OuagadougouAges Up to 18 years - NCT04425434Recruiting
Treatment plan study for children with retinoblastoma
This trial looks at care recommendations for children with retinoblastoma (a childhood eye cancer). It may help standardize the best treatment approach for different patterns of tumor spread.
OuagadougouAges Up to 18 years - NCT04427384Recruiting
Brain tumor patients treated with GammaTiles registry
This study is a patient registry for people with brain tumors who had surgery to remove as much as safely possible and then had GammaTiles placed. It mainly collects information and follow-up imaging to understand how patients do after the treatment.
Phoenix, ArizonaAges Any age - NCT04428528Recruiting
Ultrasound-like pictures that track breast tumors during chemotherapy
This study uses a special light-based imaging scan to learn more about breast masses and how tumors may respond to chemotherapy before surgery. The scan is meant to help doctors better characterize tumors and potentially track treatment response.
Toronto, OntarioAges Any age - NCT04428515Recruiting
Photoacoustic scans for untreated head and neck cancer
This study tests a special imaging scan (photoacoustic imaging) to help doctors look at head and neck cancer before treatment. It’s for people who have not had first-line therapy yet and will be starting radiotherapy.
Toronto, OntarioAges Any age - NCT04429542RecruitingPhase 1
Test of an EGFR-targeting drug for advanced solid cancers
This Phase 1 study tests the safety of BCA101 (an EGFR-targeting treatment) alone or combined with pembrolizumab. It may help people with certain EGFR-driven advanced cancers, depending on the tumor type, prior treatments, and required biopsy testing.
La Jolla, CaliforniaAges 18 years+ - NCT04430452RecruitingPhase 2
Durvalumab with or without tremelimumab after liver radiation
This study tests whether the immunotherapy drugs durvalumab (with or without tremelimumab) can help control hepatocellular carcinoma (liver cancer) after you receive palliative, targeted radiation. It especially focuses on people whose cancer continued to grow after, or without, certain prior immune therapies.
San Francisco, CaliforniaAges 18 years+ - NCT04431024Recruiting
Testing imaging and biopsy options for people with BAP1 risk
This study looks at how well advanced scans, liquid biopsy tests, and small follow-up procedures can find early mesothelioma in people with a high-risk BAP1 gene condition. It may help catch cancer earlier when treatment could work better.
Bethesda, MarylandAges 30–120 - NCT04434040RecruitingPhase 2
Atezolizumab and sacituzumab to prevent breast cancer return
This trial tests two medicines after surgery and chemotherapy to help lower the risk that triple-negative breast cancer comes back. It’s for people whose cancer still showed “residual” invasive disease after neoadjuvant (before-surgery) chemotherapy, and whose blood test shows traces of tumor DNA.
San Francisco, CaliforniaAges 18 years+ - NCT04436965RecruitingPhase 3
Standard nutrition support for malnourished nasopharyngeal cancer patients
This Phase 3 study tests whether giving a standard nutrition plan can improve nutritional status and outcomes in people with locally advanced nasopharyngeal cancer who are malnourished. It mainly checks whether nutrition support helps you tolerate treatment and do better over time.
Guangzhou, GuangdongAges 18–65 - NCT04437329RecruitingPhase 3
Nedaplatin vs cisplatin for nasopharyngeal cancer
This trial compares two chemotherapy drugs—nedaplatin versus cisplatin—in people newly diagnosed with a specific type of nasopharyngeal cancer. The goal is to see which drug works better and/or has a safer side-effect profile when given as part of standard treatment.
Guangzhou, GuangdongAges 18–65 - NCT04437160RecruitingPhase 2
Chemo after surgery for triple-negative breast cancer with leftover tumor
This Phase 2 study tests chemotherapy given after surgery for people with triple-negative breast cancer who still have cancer left after initial (neoadjuvant) chemo. It may help lower the chance the cancer comes back in people at higher risk based on leftover tumor and lymph node findings.
Beijing, Beijing MunicipalityAges 18–75 - NCT04440267RecruitingPhase 2
Tested leukemia treatment for mixed-type acute leukemia
This Phase 2 study tests a leukemia-based treatment for people with acute leukemia that doesn’t clearly belong to one type. It aims to improve outcomes for patients who meet specific health and heart/lab requirements.
Tianjin, Tianjin MunicipalityAges 14 years+
Common questions
- How many cancer clinical trials are recruiting?
- Clin2 is tracking 20,648 recruiting oncology studies from the U.S. registry right now, out of 31,565 we cover in this area in total.
- What does “Cancer” cover here?
- Studies of cancers and tumors of every type and site, from prevention to treatment. We group each study into cancer based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a cancer trial near me?
- Use the search to filter cancer studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.